Research Library
Cited summaries of the public research that underpins our scoring models, board pack and benchmark report. Use them in your own briefings.
Technology partner: MetaOptima Technology — the AI dermoscopy platform behind the peer-reviewed clinical trial below.
Peer-Reviewed Research (2026)
Pragmatic evaluation of a nurse-led, multi-disciplinary early detection model across three pop-up clinics in regional/rural SA. 509 total body skin checks performed; 24% of consumers were above-average melanoma risk; 99% would use the service again. Demonstrates a scalable workforce model for under-serviced areas — regional/rural Australia is projected to account for 47% of melanoma incidence.
Peer-Reviewed Clinical Trial (Lancet Digital Health, 2023)
Multicentre, prospective diagnostic trial (Australia & Austria) of mobile-phone-powered AI dermoscopy across 172 suspicious lesions (84 malignant) and 5,696 lesions in 66 high-risk patients. The 7-class AI algorithm was diagnostically equivalent to specialists (Δ accuracy 1.2%) and significantly superior to novice clinicians (Δ 21.5%). Real-world evidence that mobile AI dermoscopy — the same class of technology underpinning workplace screening — can match specialist accuracy at the point of care. Funded by MetaOptima Technology, our technology partner.
SCC Research Summary
1.4M+ Australians work primarily outdoors. UV exposure is 5–10× higher than indoor workers; ~22% of the workforce is occupationally exposed to solar UV.
Independent Research
$266M annual productivity loss to employers; lifetime cost of late-stage diagnosis to employer + system measured in hundreds of thousands per case.
Government Data
5-year relative survival drops from 99% at Stage I to 26% at Stage IV. Early detection is the single largest survival lever.
Authoritative Source
2 in 3 Australians will be diagnosed with skin cancer by age 70. Outdoor workers carry materially higher lifetime risk and benefit most from systematic screening.
Compliance Guidance
Employer duties under WHS legislation include controls for UV exposure as a recognised workplace hazard.
Government Data
Skin cancer carries the highest health-system expenditure of any cancer in Australia — $1.72B per year.
Technology Partner
MetaOptima is our technology partner, providing the AI-assisted dermoscopy platform behind our workplace screening model. Their mobile-phone-powered 7-class AI algorithm was clinically validated in a peer-reviewed Lancet Digital Health trial as diagnostically equivalent to specialist dermatologists for suspicious pigmented lesions — the same technology class deployed in our on-site and pop-up clinics.
The partnership lets us combine nurse-led, scalable workforce models with specialist-grade decision support — improving early detection in workplaces and in regional and rural Australia.
Want this consolidated for your board?
The 2026 Benchmark Report turns the entire evidence base into a single, board-ready reference — sector by sector.
View the Benchmark Report →